NUVB Latest Press Releases

-- November 10, 2026 --

Nuvation Bio to Present at the Jefferies Global Healthcare Conference in London PRNewswire 4:05 PM

-- November 4, 2026 --

Nuvation Bio Reports Third Quarter 2026 Financial Results and Provides Business Update PRNewswire 4:05 PM

-- November 2, 2026 --

Nuvation Bio to Present Additional Updated Phase 2 Results at 2026 Society for Neuro-Oncology Annual Meeting PRNewswire 8:00 AM

-- October 29, 2026 --

Nuvation Bio to Expand Pivotal Phase 3 SIGMA Study of Safusidenib for IDH1-Mutant Glioma to Six European Countries PRNewswire 8:00 AM

-- October 21, 2026 --

Nuvation Bio to Report Third Quarter 2026 Financial Results and Provide Business Update on November 4, 2026 PRNewswire 4:06 PM

-- September 17, 2026 --

Nuvation Bio Announces FDA Approval of Supplemental New Drug Application for IBTROZI (taletrectinib) with Updated Duration of Response in TKI-Nave Advanced ROS1-Positive Non-Small Cell Lung Cancer PRNewswire 7:30 AM

-- September 15, 2026 --

Nuvation Bio Announces New Analyses Reinforcing the Durable, Consistent Efficacy of IBTROZI (taletrectinib) Across Key Patient Subgroups in Advanced ROS1+ NSCLC at 2026 World Conference on Lung Cancer PRNewswire 8:00 AM

-- September 2, 2026 --

Nuvation Bio to Participate in Upcoming Investor Conferences PRNewswire 4:06 PM

-- August 20, 2026 --

Nuvation Bio Granted FDA Fast Track Designation for Safusidenib for Treatment of IDH1-Mutant Glioma PRNewswire 8:00 AM

-- August 6, 2026 --

Nuvation Bio Reports Second Quarter 2026 Financial Results and Provides Business Update PRNewswire 7:31 AM

-- August 4, 2026 --

Nuvation Bio to Present New Subgroup Analyses of Pivotal Data for IBTROZI (taletrectinib) in Advanced ROS1-Positive Non-Small Cell Lung Cancer at WCLC and ESMO Annual Congresses PRNewswire 8:00 AM

-- July 22, 2026 --

Nuvation Bio to Report Second Quarter 2026 Financial Results and Provide Business Update on August 6, 2026 PRNewswire 4:05 PM

-- July 20, 2026 --

Nuvation Bio Announces Positive Updated Phase 2 Data and Expansion of Safusidenib Clinical Program with Two New Studies to Explore Broad Spectrum of IDH1-Mutant Glioma PRNewswire 8:00 AM

-- July 6, 2026 --

Nuvation Bio Inc. Announces Full Exercise of Greenshoe Option in $287.5 Million Convertible Senior Notes Offering PRNewswire 5:11 PM

-- June 29, 2026 --

Nuvation Bio Announces Marketing Authorisation Application for Taletrectinib for the Treatment of Advanced ROS1-Positive Non-Small Cell Lung Cancer Validated in the United Kingdom PRNewswire 8:00 AM

-- June 25, 2026 --

Nuvation Bio Announces Pricing of Upsized Offering of $250.0 million of Convertible Senior Notes PRNewswire 11:59 PM

Nuvation Bio Announces Proposed Convertible Senior Notes Offering PRNewswire 7:00 AM

Market Data Delayed 15 Minutes